(A) Timeline of nlsEos fate mapping experiment. Fish were photoconverted at 5 dpf, treated with neomycin, then fixed and imaged 72 hr post treatment (8 dpf). (B, C, D) Maximum projections of neuromasts from sfrp1a:nlsEos (Peripheral, B), tnfsf10l3:nlsEos (AP, C), and sost:nlsEos (DV, D) fish following photoconversion and hair cell regeneration. Converted nlsEos-positive cells are shown in magenta, and brn3c:GFP-positive hair cells are shown in green. Arrowheads indicate nlsEos-positive hair cells. Scale bar = 10 μm. (E) Percentage of hair cells per neuromast labeled by nlsEos following regeneration. Sfrp1a:nlsEos (Peripheral): 3.59 ± 8.87, n = 50 neuromasts (10 fish); tnfsf10l3:nlsEos (AP): 20.28 ± 20.58, n = 50 neuromasts (10 fish); sost:nlsEos (DV): 60.87 ± 12.37, n = 50 neuromasts (10 fish); mean ± SD; Kruskal-Wallis test, Dunn’s post-test, p=0.003 (Peripheral vs. AP), p<0.0001 (Peripheral vs. DV, AP vs. DV). (F) Total nlsEos-positive support cells per neuromast prior to hair cell ablation. Sfrp1a:nlsEos (Peripheral): 14.30 ± 4.17, n = 50 neuromasts (10 fish); tnfsf10l3:nlsEos (AP): 22.8 ± 4.40, n = 50 neuromasts (10 fish); sost:nlsEos (DV): 23.86 ± 4.45, n = 50 neuromasts (10 fish); mean ± SD; Kruskal-Wallis test, Dunn’s post-test, p<0.0001 (Peripheral vs. AP, Peripheral vs. DV), p>0.9999 (AP vs. DV).